Piper Sandler analyst Allison Bratzel raised the firm’s price target on Incyte (INCY) to $102 from $82 and keeps an Overweight rating on the shares. The firm notes the company shared strong Q3 results, with Jakafi posting a $20M beat and Opzelura beating consensus by $11M, with non-GAAP EPS of $2.26 representing 63c upside from consensus. Given continued commercial momentum, coupled with key leadership changes, strategic partnerships, and pipeline prioritizations, Piper thinks the risk/reward remains favorable at current levels and remains a buyer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Why Is Prelude Therapeutics Stock (PRLD) Down 45% Today?
- Prelude Therapeutics announces exclusive option agreement with Incyte
- Prelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs
- Mizuho says Incyte myelofibrosis efficacy data look ‘promising,’ but still early
- Incyte’s INCA033989 Shows Promising Initial Results in Myelofibrosis, But Hold Rating Reflects Need for Further Data